Prostate Cancer Coverage from Every Angle

Christopher Sweeney, MBBS, on Treating Prostate Cancer With PI3K/AKT Pathway Alterations

Posted: Wednesday, February 17, 2021

Christopher Sweeney, MBBS, of Dana-Farber Cancer Institute, discusses the challenges of treating patients with metastatic castration-resistant prostate cancer and PI3K/AKT pathway alterations, a subtype with a poor prognosis. The combination of ipatasertib and abiraterone has been shown to be effective, and biomarkers may provide clues about what to expect in terms of responsiveness.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.